Royalty Pharma plc
RPRXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Valued at $35.01B, RPRX is a large-cap name in its sector. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Market Cap
$35.01B
Beta
0.43
P/E (TTM)
32.58
P/E (Fwd)
10.56
EPS (TTM)
$1.86
EPS (Fwd)
$5.74
ROE
14.0%
ROA
5.1%
Cash
$837.0M
Total Debt
$8.96B
Free CF
-$1.20B
52W Change
76.8%
Annual Financials
Cash vs Debt
Where RPRX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RPRX finished 21.67% above its 150-day moving average ($51.87) and 29.80% above its 200-day moving average ($48.62). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RPRX overbought or oversold?
At the September 3, 2026 close, RPRX's RSI(14) was 74.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Royalty Pharma plc carries $8.96B in total debt against $837.0M in cash reserves — debt is roughly 10.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$1.20B, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 14.0%, which is decent for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $2.24B (2022) to $2.38B (2025).
With a beta below 0.7, Royalty Pharma plc typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Royalty Pharma plc's trajectory.